Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Tatiana Plavina(Biogen (United States)), Bruce Cree(University of California, San Francisco), Alison Adams(St. Josef-Hospital), Robert J. Fox(Cleveland Clinic), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Pei‐Ran Ho(The University of Sydney), Ivan Nestorov(St. Josef-Hospital), Ludwig Kappos(University Hospital of Basel), Ralf Gold(St. Josef-Hospital), Kumar Kandadi Muralidharan(Biogen (United States)), Bianca Weinstock‐Guttman(Jacobs Institute), Meena Subramanyam(Jawaharlal Nehru Technological University Anantapur), Geoffrey Kuesters(Biogen (United States)), Diogo Amarante(St. Josef-Hospital), Karleyton C. Evans(St. Josef-Hospital), Yi Chen(Sichuan University of Arts and Science), Douglas Jeffery(University of New Mexico), Hans-Peter Hartung(The University of Sydney), Qunming Dong(Vertex Pharmaceuticals (United States)), Daniel D. Mikol(Cardiome (Canada)), de Sèze(Hôpital d'Hautepierre)
Cited by 92
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k